SUMMARY
Chlorphen Mal/Dex HBr/Pseudoeph HCl 0.8/3/9 mg Drops is an antihistaminic, antitussive, and decongestant drop for oral administration. Each dropperful (1 mL) contains: Chlorpheniramine Maleate, USP.............. 0.8 mg Dextromethorphan HBr, USP..................... 3 mg Pseudoephedrine HCl, USP........................ 9 mg
Chlorphen Mal/Dex HBr/Pseudoeph HCl 0.8/3/9 mg Drops is indicated for symptomatic relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold.
|
|
NEWS HIGHLIGHTS
Clinical Trials Related to Chlorphen Mal Dex HBr Pseudoeph (Chlorpheniramine / Pseudoephedrine / Dextromethorphan)
Study of AHIST in Seasonal Allergic Rhinitis Patients [Withdrawn]
Objectives:
A) To gather pharmacodynamic measurements and assess blood levels of the active ingredients
in AHIST over the dosage interval period of 12 hours.
Hypothesis: Hysteresis curves plotting each active ingredient's blood levels over a 12-hour
dosage interval will substantiate S5 Symptom Diary scores (IE: evidentiary therapeutic
window data);
B) To report subjective scores by subjects rating the efficacy of a single dose AHIST in
relieving nasal congestion, rhinorrhea, nasal itching, sneezing, and post-nasal drip over a
12-hour dosage interval.
Hypothesis: Greater than 66% of subjects will document clinically significant relief over a
12-hour period from one dose of AHIST;
C) Report any side effects or adverse drug reactions and rate the severity of any incidence.
Hypothesis: Not more than one patient will have an adverse event significant enough to
warrant withdrawal; side effects will be mild with the most frequently reported side effect
occurring in less than 10% of patients—drowsiness.
Fed Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate
the oral bioavailability of the Mallinckrodt extended release test capsule formulation of
chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a
commercially available extended release oral suspension of chlorpheniramine
polistirex/hydrocodone polistirex (Tussionex® Pennkinetic® Extended Release Oral Suspension,
Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fed conditions.
Study Evaluating Chlorpheniramine Maleate Liquid in Children and Adolescents [Completed]
Fasting Study of Chlorpheniramine Polistirex and Hydrocodone Polistirex Capsules and Tussionex� Pennkinetic� Extended Release Oral Suspension [Completed]
The objective of this open-label, randomized, two-period, crossover study was to evaluate
the oral bioavailability of the Mallinckrodt extended release test capsule formulation of
chlorpheniramine polistirex/hydrocodone polistirex compared to an equivalent oral dose of a
commercially available extended release oral suspension of chlorpheniramine
polistirex/hydrocodone polistirex (Tussionex® Pennkinetic® Extended Release Oral Suspension,
Celltech Pharmaceuticals, Inc.) in a test group of healthy subjects under fasting
conditions.
StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study [Active, not recruiting]
This active vs active comparative trial will evaluate the safety and efficacy of incremental
doses of atropine in combination with pseudoephedrine 120 mg/chlorpheniramine 8 mg in adult
patients with a history of seasonal allergic rhinitis. Hypotheses are defined by total nasal
symptom scores (TNSS) recorded by subjects in diaries where efficacy will be established by
statistical significance where p < 0. 05.
|
|
Page last updated: 2010-01-21
|